Comparing the current results to its competitors, Penumbra Inc reported Revenue increase in the 1 quarter 2026 by 15.62 % year on year. The sales growth was above Penumbra Inc's competitors' average revenue growth of 5.22 %, achieved in the same quarter.
Penumbra Inc's Comment on Competition and Industry Peers
The company operates in the medical device industry, which is highly competitive and subject to rapid change due to new product introductions and market activities. It competes with several manufacturers and distributors of neuro and vascular medical devices, including Boston Scientific, Medtronic, Stryker (including Inari Medical), Terumo, and various private companies. These competitors are generally larger, better capitalized, and have longer operating histories, allowing them to invest more extensively in product acquisition, development, marketing, sales, and other initiatives. The company also faces competition from smaller medical device firms with limited product ranges. Competitors often possess greater name recognition, stronger relationships with healthcare professionals and payors, more established distribution networks, additional product lines, and the capacity to offer discounts or incentives. They also typically have more experience in research and development, manufacturing, clinical trials, marketing, and regulatory clearance processes.
Overall company sales advanced by 15.62 % Penumbra Inc outperformed its competitors in this segment and improved market share, to approx. 0.84 %. << More on PEN Market Share.
*Market share is calculated based on total revenue.
Edwards Lifesciences Corporations business model focuses on the development and commercialization of advanced medical technologies that enhance the diagnosis and treatment of heart disease, emphasizing innovative heart valves and critical care monitoring solutions. The company serves a diverse customer base, including hospitals and direct-to-patient markets, with a strong commitment to improving patient outcomes and quality of life.
Vaalco Energy Inc is an independent energy company primarily engaged in the exploration, development, and production of crude oil. They focus on offshore and onshore assets with a sustainable business model aimed at delivering long-term value to their stakeholders.
Cvrx Inc. operates on a business model focused on developing medical devices to treat cardiovascular diseases. The company focuses on developing implantable neurostimulation technologies to improve heart function and manage hypertension. They aim to provide innovative solutions that enable better patient outcomes and ultimately revolutionize the field of cardiovascular therapy.
Boston Scientific Corporations business model centers on creating innovative medical devices for diverse specialties, aimed at addressing unmet medical needs and enhancing patient outcomes. The company sells its products to healthcare professionals and hospitals globally, supported by robust sales and distribution networks. It prioritizes research and development to continually introduce new technologies and solutions.
Sources:
Penumbra Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Penumbra Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
